

# Fiscal Year 2021

## Syringe Services Report

Fiscal Year : 7/1/2020-6/30/2021



Syringe service metrics are calculated to determine the reach of program services. Seven syringe service providers (SSPs) exchanged syringes with clients from July 1 2020 to June 30 2021: Utah Harm Reduction Coalition, One Voice Recovery, Utah Naloxone, Soap 2 Hope, Southeast Utah Health Department, Martindale Clinic, and Beyond Addiction Mosaic. Martindale Clinic began providing exchange services in February 2021. Beyond Addiction Mosaic began providing exchange services in March 2021.


**Table 1. Syringe Service Program metrics in fiscal year**

Metric	Q1	Q2	Q3	Q4	Year
Syringes In	282,546	306,795	331,133	356,816	1,277,290
Syringes Disposed Elsewhere*	26,355	34,102	28,212	26,513	115,182
Syringes Out	348,127	401,820	404,641	440,897	1,595,485
Return Ratio**	1.23	1.31	1.22	1.24	1.25
Return Ratio (with disposed elsewhere)	1.13	1.18	1.13	1.15	1.15
Total Unique Clients Served	1,507	1,433	1,423	1,688	3,541
Total Encounters	2,213	5,127	4,894	6,132	18,366
New Participants	500	468	413	522	1,903

\*Self reported proper disposal

\*\*"Return Ratio" is Syringes Out divided by Syringes In.

**Figure 1. Return Ratio by quarter and in fiscal year**



During the 2020-2021 fiscal year, the return ratio varied by quarter, but averaged to 1.25 over the year. Or for every 1.25 syringes distributed, SSPs received one back at an exchange event.

The return ratio syringe metric is calculated by dividing the number of syringes distributed out by the number of used syringes collected. This ratio is calculated with the number of syringes turned in directly to syringe service providers, combined with the number of syringes that are reported to be properly disposed of elsewhere.

**Table 2. Naloxone provided by SSPs**

Naloxone	Q1	Q2	Q3	Q4	Year
Doses Distributed	651	940	703	1,320	3,614
Reversals Reported	22	32	12	30	96


At each syringe exchange encounter, participants are asked if they were the recipient of an overdose reversal with naloxone, or if they performed a reversal for someone else in the time since their last visit. It is possible that a participant could report more than one reversal per month, or encounter. Participants are given the option to decline to answer this question.

Reversals are defined as survival of an individual when one or more naloxone doses were administered to the person during a suspected overdose event. Additional naloxone purchased by Utah Naloxone and distributed by syringe service providers is not included in doses distributed.

**Table 3. Gender reported by clients in the fiscal year**

Gender	Q1 (N)	Q1 (%)	Q2 (N)	Q2 (%)	Q3 (N)	Q3 (%)	Q4 (N)	Q4 (%)	Year (N)	Year (%)
Male	915	60.7%	757	59.3%	541	57.1%	678	58.6%	1,357	60.2%
Female	578	38.3%	512	40.1%	400	42.2%	475	41.0%	876	38.9%
Trans/ Nonconforming	7	0.5%	3	0.2%	2	0.2%	3	0.3%	10	0.4%
Declined	7	0.5%	4	4.0%	5	0.5%	2	0.2%	9	0.4%
Unique Clients	1,507		1,276		948		1,158		2,252	

**Figure 2. Gender reported by clients in the fiscal year**




New clients are asked a series of intake questions at their first visit, including questions about gender and race. All data on gender and race is self-reported. Clients are not asked intake questions about gender or race during follow-up syringe exchange encounters. If a client wants to change the self-reported data in their record, they may do that at any time. Gender data is not available for all participants during the fiscal year. The number of unique clients that data is available for is shown in the table above.

**Table 4. Race reported by clients in the fiscal year**

Race	Q1 (N)	Q1 (%)	Q2 (N)	Q2 (%)	Q3 (N)	Q3 (%)	Q4 (N)	Q4 (%)	Year (N)	Year (%)
White	1,245	82.6%	1,049	82.2%	768	81.1%	901	77.9%	1,766	78.5%
Declined/Unknown	72	4.8%	62	4.9%	46	4.9%	58	5.0%	122	5.4%
Other	49	3.3%	40	3.1%	31	3.3%	56	4.8%	88	3.9%
Black	47	3.1%	37	2.9%	23	2.4%	43	3.7%	84	3.7%
Multiple	28	1.9%	26	2.0%	35	3.7%	42	3.6%	80	3.6%
American Indian/ Alaskan Native	40	2.7%	33	2.6%	30	3.2%	28	2.4%	62	2.8%
Native Hawaiian/ Pacific Islander	19	1.3%	20	1.6%	10	1.1%	21	1.8%	37	1.6%
Asian	7	0.5%	9	0.7%	5	0.5%	9	0.8%	13	0.6%
Unique Clients	1,507		1,276		948		1,158		2,252	

Race data is not available for all participants during the fiscal year. The number of unique clients that data is available for is shown in the table above.

**Figure 3. Race reported by clients in the fiscal year**




**Table 5. HCV/HIV testing and identification in fiscal year**

HCV Testing*	Q1	Q2	Q3	Q4	Year
Tested	51	30	61	28	224
Tested Positive	10	9	23	12	80
Positivity Rate	19.6%	30.0%	37.7%	42.9%	35.7%
Reported HCV positive at intake	42	39	48	43	172
HIV Testing*	Q1	Q2	Q3	Q4	Year
Tested	48	33	76	30	243
Tested Positive	2	1	0	0	4
Positivity Rate	4.2%	3.0%	0.0%	0.0%	1.6%
Reported HIV positive at intake	5	4	5	2	16

\*All tests are rapid antibody tests


**Figure 4. HCV Testing in fiscal year**



Three syringe service providers provided rapid tests to clients, shown in the table above and figures to the left (Utah Harm Reduction Coalition, One Voice Recovery, and Southeast Utah Health Department). All SSPs collect information on HIV and HCV status upon intake.

Two syringe service providers offer testing in their clinic locations, which is not reported here (Utah Naloxone and Martindale Clinic).

**Figure 5. HIV Testing in fiscal year**



Syringe service providers who do not provide testing, provide referrals to testing sites and can make testing appointments for clients.

All syringe service providers must offer referrals for HCV and HIV testing at each syringe encounter, regardless of testing capability.


**Table 6. Referrals in fiscal year**

Referrals	Q1	Q2	Q3	Q4	Year
<b>Substance Use Treatment</b>					
Written	4,791	4,282	4,313	4,435	17,821
Verbal	1,945	1,919	1,524	2,563	7,951
Active	21	98	77	18	214
<b>HIV/HCV Testing</b>					
Written	4,787	4,275	4,315	4,434	17,811
Verbal	3,528	3,325	2,903	3,905	13,661
Active	33	125	107	56	321
<b>Overdose Prevention\Naloxone</b>					
Written	4,791	4,276	4,314	4,433	17,814
Verbal	3,521	3,357	2,989	3,937	13,804
Active	368	623	449	330	1,770

Substance Use Treatment, HIV/HCV Testing, and Overdose Prevention/Naloxone referrals are required at each encounter for all providers. Providers may offer more than one type of referral. For example, a provider may speak with a client about HIV testing, and also schedule an appointment for that client to be tested.

The figure below shows the number of written, verbal, and active (“warm hand off”) referrals for each service.

**Figure 6. Referrals in fiscal year, by type**



**Table 7. Substances reported at intake, in fiscal year**

Substance	Q1	Q2	Q3	Q4	Year
New Participants	500	468	413	522	1,903
Meth/Speed	355	356	312	421	1,444
Heroin	346	303	262	357	1,268
Cannabis/Marijuana	79	128	141	167	515
Alcohol	41	71	61	120	293
Crack/Cocaine	53	59	47	73	232
Tobacco	27	39	63	88	217
Benzodiazepines	18	36	30	52	136
Prescription Pain Medicine	7	20	20	39	86
Suboxone	13	24	23	25	85
Fentanyl	-	10	12	25	47
Spice	9	7	12	17	45
Gabapentin	2	6	12	23	43
Methadone	9	5	8	15	37
Subutex	5	5	4	5	19

Fentanyl data not collected in Q1

Data is collected from individuals who use the syringe service program at intake, or return to the program from jail or residential treatment center. Individuals are asked what substances they have used in the past 30 days.

If an individual has used more than one substance, they mark all substances they used.


Data collection on fentanyl use reported at intake began in quarter 2.

**Table 8. Substances reported at intake, in fiscal year, by percentage**

Substances	Q1	Q2	Q3	Q4	Year
Meth/Speed	71.0%	76.1%	75.5%	80.7%	75.9%
Heroin	69.2%	64.7%	63.4%	68.4%	66.6%
Cannabis/Marijuana	15.8%	27.4%	34.1%	32.0%	27.1%
Alcohol	8.2%	15.2%	14.8%	23.0%	15.4%
Crack/Cocaine	10.6%	12.6%	11.4%	14.0%	12.2%
Tobacco	5.4%	8.3%	15.3%	16.9%	11.4%
Benzodiazepines	3.6%	7.7%	7.3%	10.0%	7.1%
Prescription Pain Medicine	1.4%	4.3%	4.8%	7.5%	4.5%
Suboxone	2.6%	5.1%	5.6%	4.8%	4.5%
Fentanyl	-	2.1%	2.9%	4.8%	2.5%
Spice	1.8%	1.5%	5.6%	3.3%	2.4%
Gabapentin	0.4%	1.3%	2.9%	4.4%	2.3%
Methadone	1.8%	1.1%	1.9%	2.9%	1.9%
Subutex	1.0%	1.3%	1.0%	1.0%	1.0%

Fentanyl data not collected in Q1


**Figure 7. Substances reported at intake, in fiscal year, by percentage**



Data is collected from individuals who use the syringe service program at intake, or return to the program from jail or residential treatment center. Individuals are asked what substances they used in the past 30 days.

Data collection on fentanyl reported at intake began in quarter 2.

**Figure 8. Most common substances reported at intake, in fiscal year, by percentage**



The most common six substances reported at intake are displayed in the figure above. Most clients report using meth or heroin. Other commonly reported substances above are crack, marijuana, alcohol, and tobacco.

SSPs record the ZIP code location of each SSP encounter they have with each participant. The map below displays the ZIP code location of SSP encounters for the fiscal year. ZIP code locations with higher number of encounters are marked by darker shades of blue.

Figure 9. ZIP Code of each Syringe Service encounter reported, in fiscal year







Figure 10. ZIP Code of encounters, in fiscal year, Salt Lake County



The figures to the left display zoomed in views of the map on page 8.

The most SSP encounters occur Salt Lake County, in ZIP codes 84116, 84105 and 84115. There are also notable numbers of encounters near Ogden in Weber County, and near Price in Carbon and Emery counties.

Figure 11. ZIP Code of encounters, in fiscal year, Weber County




Figure 12. ZIP Code of encounters, in fiscal year, Carbon and Emery County




Table 10. ZIP Code of Encounters, in fiscal year

ZIP	N	ZIP	N
84116	4,310	84094	14
84105	3,017	84062	13
84115	2,189	84057	12
84101	599	84014	11
84111	397	84016	11
84119	355	84065	10
84047	328	84601	9
84501	283	84011	8
84074	219	84528	8
84107	210	84043	6
84401	192	84402	6
84104	178	84087	5
84102	177	84109	5
84103	174	84003	4
84121	166	84010	4
84520	118	84405	4
84123	117	84015	3
84542	115	84092	3
84070	97	84190	3
84106	76	84041	2
84403	56	84071	2
84124	48	84090	2
84129	44	84108	2
84117	40	84113	2
84088	39	84310	2
84029	38	84404	2
84095	37	84415	2
84020	33	84005	1
84118	33	84017	1
84084	31	84046	1
84120	27	84049	1
84081	26	84058	1
84044	22	84060	1
84114	18	84075	1
84067	17	84085	1
84054	16	84097	1
84096	15	84125	1
84128	15	84126	1
84093	14	84157	1